Policy to Review Limited Use of The Drug “Chloroquine” Patients May 24 at 10:08
In response to the publication of research on chloroquine, a treatment for malaria, which has been pointed out as a potential effect on the treatment of the new coronavirus, the French government has announced a policy to review regulations that allow limited use of the disease on patients.
Although malaria and other therapeutic drugs such as chloroquine and a type of “hydroxychloroquine” may have the potential to be effective in the treatment of the new coronavirus, a group of researchers in the United States and Switzerland published the results of a study that said that “no effect was observed” from the analysis of data for approximately 1,000,000 people in the United States and Switzerland, and that some patients who were administered had abnormal heart rate.
In response, France’s Health Minister Belan posted on Twitter on Sunday, “We have asked a committee of experts to review the results of the study and review the rules for use within hours.”
France currently allows limited use of hydroxychloroquine for clinical trials or patients with severe symptoms, but it is expected to review this provision in response to the results of the study.
U.S. President Trump has made it clear that he is taking “hydroxychloroquine”, but the World Health Organization has warned of its use, saying it does not know if it is effective, and since the beginning of this month, there have been a series of negative studies on the effect.